M. L. Citron, D. A. Berry, C. Cirrincione, C. Hudis, E. P. Winer, W. J. Gradishar, et al., “Randomized Trial of DoseDense versus Conventionally Scheduled and Sequential versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/ Cancer and Leukemia Group B Trial 9741,” Journal of Clinical Oncology, Vol. 21, No. 8, 2003, pp. 1431-1439. doi:10.1200/JCO.2003.09.081

has been cited by the following article:

• TITLE: Dose-Dense Regimen of Cisplatin and Infusional Fluorouracil in Advanced Gastric Cancer—A Single Institution Experience

  AUTHORS: Ofer Purim, Yulia Kundel, Roni Shapira, Baruch Brenner

  KEYWORDS: Gastric Cancer; Dose-Dense; Cisplatin; Fluorouracil

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.2, April 15, 2013

  ABSTRACT: Chemotherapy with continuous infusion of 5-fluorouracil and cisplatin in a monthly schedule is one of the most common regimens in the treatment of advanced gastric cancer. In this study, we evaluated the efficacy and safety of a dosedense administration of this regimen in this patient population. Sixty-six consecutive patients with previously untreated histologically confirmed unresectable or metastatic gastric adenocarcinoma were treated with a 2-hour infusion of cisplatin 100 mg/m2 followed by continuous infusion of 5-fluorouracil 1000 mg/m2/day for 5 days, every 21 days. The most common grade ≥3 toxicities were fatigue (42%), nausea/vomiting (30%) and leucopenia (12%). Four patients (6%) died from treatment-related toxicity. The response rate was 35%, the median progression-free survival was 4.3 months and the median survival was 5.9 months. In light of these results, the dose-dense approach seems to offer little, if any, benefit compared with the standard regimens.